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Acinetobacter baumannii is a Gram-negative bacterial pathogen responsible for a
range of nosocomial infections. The recent rise and spread of multidrug resistant A.
baumannii clones has fueled a search for alternative therapies, including bacteriophage
endolysins with potent antibacterial activities. A common feature of these lysins is the
presence of a highly positively charged C-terminal domain with a likely role in
promoting outer membrane penetration. In the current study, we show that the C-terminal
amino acids 108-138 of phage lysin PlyF307, named P307, alone was sufficient to kill A.
baumannii (>3-logs). Furthermore, P307 could be engineered for improved activity, the
most active derivative being P307SQ-8C (>5-log kill). Both P307 and P307SQ-8C showed
high in vitro activity against A. baumannii in biofilms. Moreover, P307SQ-8C exhibited
MICs comparable to levofloxacin and ceftazidime and acted synergistically with
polymyxin B. While the peptides were shown to kill by disrupting the bacterial
cytoplasmic membrane, they did not lyse human red blood cells or B cells; however,
serum was found to be inhibitory to lytic activity. In a murine model of A. baumannii
skin infection, P307SQ-8C reduced the bacterial burden by ~2-logs in 2 h. This study
demonstrates the prospect of using peptide derivatives from bacteriophage lysins to treat
topical infections and remove biofilms caused by Gram-negative pathogens.
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1.1

CHAPTER 1 – INTRODUCTION
Acinetobacter baumannii
Acinetobacter baumannii is a strictly aerobic Gram-negative bacterium and

belongs to the family Moraxellaceae. As an opportunistic pathogen, it causes hospitalacquired or nosocomial infections worldwide (1). The treatment options are greatly
limited by its intrinsic and acquired resistance to all classes of antibiotics (2, 3).
1.1.1 History
The designation of A. baumannii has changed a great deal over time. When first
reported by Beijerinck in 1911, A. baumannii was characterized as a soil bacterium and
was called Micrococcus calcoaceticus (4, 5). Only in the 1950s did it acquire its current
genus identification Acinetobacter after being known under various genera, such as
Achromobacter anitratus, Moraxella lwoffii, Neisseria winogradskyi, to name just a few.
Current nomenclature, suggested by Brisou and Prevot in 1954, stemmed from the
bacterium’s non-motile phenotype (akinetos meaning non-motile in Greek) and was
officially recorded with a single species A. calcoaceticus in Bergey’s Manual of
Systematic Bacteriology in 1974 (6, 7). Presently the Acinetobacter genus contains over
50 species among which A. baumannii, A. calcoaceticus, A. haemolyticus, A.
nosocomialis and A. pittii are of high clinical relevance and A. baumannii is the most
prominent with highest morbidity and mortality rate (6-8).
Not only has the nomenclature evolved but the antibiotic susceptibility has also
changed over the last century for A. baumannii. During the 1960s and early 70s,
nosocomial infections by Acinetobacter had already been reported in Europe and the
United States despite limited methods for pathogen identification. The etiologic agents of
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these outbreaks, still called Acinetobacter anitratus, were of low pathogenicity and could
be easily controlled by β-lactams, sulfonamides and aminoglycosides (9). However,
beginning in late 70s, 80s and 90s, these antibiotics had progressively become ineffective
and multidrug-resistant clones emerged worldwide (10, 11). In addition, advances in
molecular techniques during these decades enabled the identification of baumannii
species as the cause of the majority of Acinetobacter infections (6). In the 2000s and
2010s, problems with antibiotic-resistant A. baumannii worsened resulting in the
establishment of surveillance networks worldwide to increase awareness and better
containment (6). Notably in 2006, The Infectious Diseases Society of America included
A. baumannii in the list of ESKAPE pathogens (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa and
Enterobacter spp.) for which only limited treatment options were available (12).
Moreover, in February 2017, the World Health Organization (WHO) emphasized the
urgent need for new drugs against this pathogen by listing Acinetobacter in the most
critical category on which research and development (R&D) efforts for new antibiotics
should be focused (13). A. baumannii has risen from a harmless bacterium to one of the
most clinically severe pathogens in the past century (Figure 1.1). To stay ahead of this
pathogen, diverse strategies must be concurrently employed, including but not limited to
prevention and control, antibiotic stewardship, as well as novel therapeutic development.
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MDR – multidrug resistant; XDR – extensively drug resistant; PDR – pandrug resistant;
TATFAR – Transatlantic Taskforce on Antimicrobial Resistance; CDC - Center of
Disease Control and Prevention; SENTRY, ReLAVRE and RHOVE – antimicrobial
surveillance program
Figure 1.1 Significant events in the history of A. baumannii.
The timeline consists of three milestones, (i) awareness and diagnosis, (ii) rise of
antibiotic resistance, and (iii) resistance containment and surveillance efforts by
international organizations. Adapted by permission (Creative Commons Attribution
License) from Hindawi Publishing Corporation: Journal of Pathogens (6), copyright
2016.
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1.1.2 Prevalence and pathogenesis
A. baumannii is an increasingly significant opportunistic pathogen worldwide (2).
Its natural habitats are soil and water. In healthy children and immuno-compromised
adults, it can cause community-acquired respiratory tract infections (7). Communityacquired pneumonia is currently limited to the tropical regions of the world and occurs
during warm and humid months (14). However, nosocomial infections are prevailing in
healthcare facilities worldwide. The important reservoirs in hospital outbreaks are
patients, healthcare workers and equipment (15). A. baumannii also persists for long
periods on abiotic surfaces under dry conditions (16). From contaminated indwelling
devices, surgical equipment and ventilators, A. baumannii can infect various body sites
(Figure 1.2) and cause meningitis, keratitis, opthalmitis, wound, respiratory and urinary
tract infections, pneumonia and bacteremia (17). According to the CDC report in 2013,
7,300 clinical isolates out of 12,000 Acinetobacter cases were multi-drug resistant
(untreatable by three or more antibiotic categories) and 500 deaths were attributed to
those infections annually in the United States alone (18). Given the widespread
prevalence and severe pathogenesis, it is essential to develop new strategies to control A.
baumannii in healthcare settings.
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Figure 1.2 Pathogenesis and virulence of A. baumannii.
A. baumannii colonizes different parts of the body and causes infections when
opportunities arise (e.g. weakened immune system, skin lesions, etc.) The pathogen has
high tolerance to environmental stress, creating inanimate reservoirs in healthcare
settings. With its varied virulence factors and antibiotic resistance, A. baumannii is
indeed a formidable foe in hospitals. Reprinted by permission from Macmillan Publishers
Limited: Nature Reviews Microbiology (17), copyright 2007.
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1.1.3 Virulence and antibiotic resistance
A. baumannii employs several virulence factors to compromise host cells and
evade immune system (Figure 1.2). The factors include outer membrane proteins (Omp),
secretion systems, toxins, iron-chelating siderophores, capsule and lipopolysaccharide
(LPS). Like other Gram-negative bacteria, A. baumannii utilizes Omp for adherence,
invasion and cytotoxicity, e.g. OmpA has been shown to be essential for epithelial cell
binding and for producing outer membrane vesicles that deliver virulence factors to
human host cells (19-22). The Type II secretion system is used to secrete lipases,
proteases and toxins that are important for in vivo fitness and pathogenesis (23). After
invasion, A. baumannii survives in iron-limiting host environments by utilizing
siderophores (24). Last, but not least, A. baumannii achieves serum resistance, eludes
complement, neutrophils and antibodies by capsule (25) and modified LPS (26).
Besides the virulence factors, A. baumannii possesses assorted mechanisms of
antibiotic resistance (27). Being naturally competent, the pathogen is capable of taking up
environmental DNA for increased survival advantages (28). Other modes of horizontal
gene transfer such as plasmid conjugation and bacteriophage transduction have resulted
in the expansion of its chromosomal repertoire for drug resistance (7). The intrinsic and
acquired resistance mechanisms (Table 1.1) include low permeability that limits
antibiotic uptake, efflux pumps that decrease intracellular antibiotic concentration,
biofilm formation that restricts metabolism to attenuate antibiotic effect, antibiotic target
site mutations and antibiotic-deactivating enzymes (27). As a result, most of A.
baumannii clinical isolates these days are either multi-drug resistant (MDR) or
extensively drug resistant (XDR or susceptible to only one or two classes of antibiotics)
or pan-drug resistant (PDR or resistant to all antibiotics).
6

1.1.4 Treatment
A. baumannii has successfully overcome most of the clinically approved
antibiotics with one or more of the resistance mechanisms mentioned above. As such, the
treatment options are limited. The antibiotics for A. baumannii infections have
traditionally been cephalosporins, sulbactam, carbepenems, rifampin, fluoroquinolones,
aminoglycosides, tetracyclines and polymyxins (Table 1.1). The first three classes, being
of β-lactam family, target the peptidoglycan synthesis and A. baumannii neutralizes them
by class A-D β-lactamases and penicillin-binding proteins (PBPs). To counteract
rifampin, fluoroquinolones and aminoglycosides, A. baumannii strains with mutations in
the drug binding sites of RNA polymerase, DNA topoisomerase and ribosome
respectively have arisen. Tetracyclines, protein synthesis inhibitors, are blocked by Tet
proteins that bind to 70S ribosome for protection. Polymyxins kill A. baumannii by
interacting with LPS through positively charged Dab (α,γ-diaminobutyric acid) residues
and destabilizing the outer membrane. Even the drugs of last resort, polymyxins are
marred with suboptimal pharmacokinetics and safety issues as well as resistance by LPS
modification. Currently, PDR A. baumannii infections are treated with combination
therapy, i.e. two or more drugs that are shown to have in vitro synergy (e.g. colistin and
rifampin). However, clinical trial data relevant to the efficacy of mono therapy vs.
combination therapy are limited since most of the latter have so far been salvage options
for severe cases (29). In view of the lack of novel antibiotic class to treat A. baumannii
and the increasing threat of drug resistance, alternative strategies such as phage-based
therapy must be considered and analyzed to fill the unmet need.
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Table 1.1 Antibiotics versus A. baumannii (29)
Classes of

Targets

Resistance mechanisms

Cell wall synthesis

Acinetobacter-derived cephalosprinase

antibiotics
Cephalosporins

(ADC), extended spectrum β-lactamases
(ESBL)
Carbepenems

Cell wall synthesis

Carbepenamases (OXA-groups, metalloβ-lactamases), reduced permeability,
active efflux

Sulbactam

β-lactamases or PBPs

Reduced expression of the targets

Rifampin

RNA polymerase

RNA polymerase modification, rifampin
modifying enzyme, active efflux

Aminoglycosides

16S ribosomal RNA

16S ribosomal RNA modification,

(protein synthesis)

aminoglycoside modifying enzymes

DNA gyrase and

Modifications in the quinolone resistance

topoisomerase

determining region, active efflux

Colistin

LPS

LPS modification or loss

Tetracyclines

30S ribosomal RNA

Ribosomal protection proteins, active

(protein synthesis)

efflux

Fluoroquinolones
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1.2

Alternative antibacterial agents

1.2.1 Bacteriophages
The interest in bacteriophage therapy has been rekindled by the rise of drugresistant bacteria together with the lack of new antibiotics in the R&D pipeline (30). The
discovery and characterization of phages in 1917 and the subsequent demonstration of
their therapeutic potential predated the beginning of antibiotic era by 11 years. However,
after the industrialization of penicillin and subsequent drugs, only the former Soviet
Union and Eastern Europe continued to pursue phage studies and use phage cocktails to
treat bacterial infections. The rest of the world had switched away from phage
therapeutics to antibiotics for a number of reasons: efficacy, safety, resistance,
manufacturing (31). Now, with the imminent possibility that we may be entering a postantibiotic era, western research institutions and government agencies are re-considering
this century-old biological approach to kill bacteria (32, 33).
Before phages can be introduced to clinics in the western world, barriers must be
overcome to obtain regulatory approval (34). A few of the hurdles originate from the
nature of phage reproduction. Phages, as viruses of bacteria, can adopt lysogenic or lytic
life cycles to multiply. After injecting their DNA into bacteria, temperate phages can
display lysogenic cycle and replicate along as prophages until environmental cues induce
them to enter a lytic cycle. On the other hand, virulent phages display lytic cycle only and
assemble phage progeny using cellular machineries of bacteria. The lytic cycle
culminates in bacterial lysis and release of phages to infect neighboring bacteria (Figure
1.3). Therefore, lytic phages, regardless of being virulent or temperate, could
theoretically multiply at the site of application and lower the bacterial burden to control
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infections. However, the use of temperate phages can spread antibiotic resistance genes
since phages can act as carriers of genetic materials among bacteria. Another safety
concern is the activation of detrimental inflammatory responses to the released bacterial
components (and endotoxins in the case of Gram-negative bacteria) by massive bacterial
lysis. In addition, phages are often strain-specific and phage cocktails are required to
cover a single species of pathogen. On the flip side, the specificity can sometimes limit
the unintended killing of commensal microflora. Like antibiotics, phage cocktails can
become ineffective as bacteria develop resistance. Therefore the treatments must be
monitored and modified. Phage resistance, however, is more easily tackled than antibiotic
resistance due to the tremendous diversity of phages for some species in nature resulting
from the arms race between phages and bacteria through hundreds of millions of years.
Unfortunately, the diversity could mean more regulatory requirements (31, 34). For these
reasons and others, phages have yet to appear in western clinics.
Despite the barriers and challenges, a number of strategies are in place to bring
the phages from bench to bedside. One such approach is genetically engineering phages
for different purposes. Some engineering tactics include creating: phages with reduced
lysis to mitigate inflammatory responses; phages that increase antibiotic susceptibility of
bacteria; phages that target pathogens with DNA sequence specificity, e.g. antibiotic
resistance genes; phages with broader host ranges and so forth (35). Along with these
creative scientific efforts, more clinical data are required to acquire regulatory approval.
Although the long-established use of phage therapy in Russia, Poland and Georgia should
have warranted the efficacy and safety, those clinical trials were not conducted with
appropriate controls, and so the Eastern European experience has not provided any useful
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proof of efficacy by Western standards. To fill this knowledge gap, the Phagoburn
clinical trial, funded by European Commission, is in progress to access the efficacy and
safety of phages in treating burn wounds infected by Escherichia coli or Pseudomonas
aeruginosa (ClinicalTrials.gov Identifier NCT02116010). The results from all the
scientific and clinical endeavors may pave the way for phages towards clinical use.

Figure 1.3 Life cycles of virulent and temperate phages.
After phage attachment and DNA injection into host bacteria, virulent phages display
lytic cycle whereas temperate phages can enter either lytic or lysogenic cycle. During the
lytic cycle, phages multiply inside bacteria and the fate of the host is lysis. On the other
hand, phages replicate along with host bacteria as prophages during the lysogenic cycle.
The host bacteria or lysogens survive until prophages re-enter lytic cycle by environment
cues (e.g. UV damage to DNA). As phages multiply, they can package bacterial DNA
and bring about transduction or phage-mediated horizontal gene transfer among bacteria.
Adapted by permission from American Society for Microbiology: Antimicrobial Agents
and Chemotherapy (31), copyright 2001.
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1.2.2 Phage lysins
Just as bacterial defenses against antibiotics are multipronged, the development of
ammunition against bacterial pathogens must progress in a multifaceted fashion. The
regulatory bottleneck for phages has prompted innovations in bactericidal phage products
such as endolysins (lysins). These are enzymes used by phages to degrade the bacterial
cell wall for lysis at the end of the lytic cycle. They are classified as peptidoglycan
hydrolases and lyases that cleave a variety of bonds in the bacterial peptidoglycan (36).
With few exceptions such as PlySs2 that kills both Streptococcus suis and
Staphylococcus aureus (37), the target bacteria of each lysin fall within a single genus or
species. Recombinant lysins against Gram-positive bacteria have been shown to be
effective bactericidal agents that cause hypotonic lysis (e.g. PlyC against Streptococcus
spp. (38), PlyG against Bacillus anthracis (39), etc.) Typically, each lysin is made up of
one or two N-terminal catalytic domains (CD) and a C-terminal cell wall binding domain
(CWBD) (40), with the notable exception of PlyC, a multimeric enzyme comprised of a
catalytic PlyCA subunit and a binding PlyCB octamer) (38). Compared to phages, lysins
present fewer regulatory challenges since cocktails are unnecessary and there is virtually
no concern for resistance development or spread of antibiotic resistance genes. The
immunogenicity of lysins is also negligible but inflammatory responses could be
triggered by dead bacterial components. Overall, lysins are promising antimicrobials
against Gram-positive bacteria (40).
In contrast, the Gram-negative counterparts are relatively less active because the
outer membrane largely limits the accessibility of subjacent peptidoglycan (Figure 1.4).
Different strategies have been employed to increase the membrane permeability to lysins,
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including the use of the chelating agent EDTA (41, 42), and the modification of lysins
with either highly charged/hydrophobic N-/C-terminal extensions (43) or other
membrane translocating domains (44, 45). The success of each approach varies in terms
of efficacy increase and clinical applicability.
Nonetheless, a few naturally active lysins have been identified and characterized,
e.g. LysAB2 (46) and PlyF307 (47). LysAB2 was isolated from lytic phage ΦAB2 and
was shown to have bactericidal activities against Streptococcus sanguis, A. baumannii
and E. coli (46). On the other hand, PlyF307 was identified as the most active lysin
among those isolated by screening for inducible lysis genes cloned from a genomic
library of prophages from 13 A. baumannii strains. It was shown to be specifically active
against A. baumannii and to be able to rescue mice from lethal bacteremia (47). These
lysins are capable of killing A. baumannii in spite of the outer membrane barrier. Both
LysAB2 and PlyF307 employ distinct domain structures. Instead of the conventional CDCWBD motif, they are composed of an N-terminal lysozyme-like domain and a Cterminal positively charged peptide (Figure 1.5). The C-terminus of LysAB2 putatively
forms an amphipathic helix and without it, LysAB2 was shown to lose 40% of its
bactericidal activity. It has also hypothesized that the positively charged peptide promotes
the membrane trespassing (46). This project focuses on the characterization of such a
peptide from PlyF307 as an antimicrobial peptide against A. baumannii.
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Figure 1.4 Simplified cell wall structures of Gram-positive and Gramnegative bacteria.
Recombinant phage lysins can effectively cleave the exposed peptidoglycan and bring
about hypotonic lysis in Gram-positive bacteria. In contrast, Gram-negative phage lysins
have only limited access to their peptidoglycan substrate because of the outer membrane.
Adapted by permission from Taylor andFrancis Group: Janeway’s Immunobiology, 8th
Edition (48), copyright Garland Science 2012.
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Figure 1.5 Putative conserved domains of LysAB2 and PlyF307.
According to a National Center for Biotechnology Information Basic Local Alignment
Search Tool (BLAST) search, both LysAB2 and PlyF307 contain lysozyme-like domains.
The stars (*) mark the putative amphipathic helix (46) in LysAB2 (amino acids 113-145)
and the similar region with a high positive charge (+7) in PlyF307 (amino acids 108138).
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1.2.3 Antimicrobial peptides
Antimicrobial peptides (AMPs) represent an important class of weapons in the
fight against bacteria. They are ubiquitous in all living organisms and come in different
sequences and structures, e.g. cationic LL-37 human cathelicidin with an amphipathic αhelix (49), cysteine-rich pig protegrin-1 with anti-parallel β-strands (50), anionic human
dermcidin with α-helix that forms hexameric bundle (51), antimicrobial peptide from
human hepatitis B virus core protein arginine-rich domain (HBc ARD) (52) and so on.
Like antibiotics, they have varied mechanisms of action, but primarily kill by
permeabilizing the membrane. While they show great potential for clinical use, AMPs
also present several safety concerns including toxicity and resistance development.
Membrane permeabilization by AMPs is usually concentration dependent. Although
mammalian membranes are spared because of the differences in lipid compositions, the
selectivity could be nullified at higher doses (53). Similarly, the likelihood is low for
bacteria to become resistant to AMPs. However, the immune evasion by pathogens could
be exacerbated if bacteria do develop resistance that is cross reactive to human AMPs, a
crucial part of innate immunity (54). Even with these safety concerns, a few AMPs are in
clinical trials for topical applications (53), indicating that AMPs are viable options to
combat antibiotic resistance threat.
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1.3

AIMS
The emergence of PDR A. baumannii severely diminishes the treatment options

for this opportunistic pathogen. With a growing interest in the use of phages, several
phages that infect A. baumannii have been identified and characterized. However, their
restricted spectrum (killing only ∼60% of A. baumannii isolates) limits the effectiveness
of such phages as therapeutic agents (55-57). By comparison, the lysins are active against
A. baumannii as a species and those with higher bactericidal activities comprise an Nterminal catalytic domain and a highly positively charged C-terminal peptide (46, 47).
Considering the atypical domain composition, we tested the hypothesis that the peptide
contributes to the lysins’ activities by destabilizing the outer and inner membranes. We
also aim to investigate the applicability of such peptides as AMPs against drug resistant
A. baumannii.
To achieve these objectives, we characterized the positively charged C-terminus
of A. baumannii phage lysin PlyF307 as P307. We also designed four derivatives and
performed bactericidal assays to compare their activities. For the most active derivative
and P307, we determined their minimum inhibitory concentrations (MIC) and synergies
with antibiotics. After examining their selectivity in permeabilizing membranes, toxicity
and serum tolerance, we proceeded to study their effectiveness in clearing A. baumannii
from mouse skin infections. With this study, we aim to demonstrate the prospect of using
peptide derivatives from lysins as antibacterial agents against Gram-negative pathogens.
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2
2.1

CHAPTER 2 – LYSIN-BASED ANTIMICROBIAL PEPTIDES
MATERIALS AND METHODS

2.1.1 Peptides
2.1.1.1 Identification, modifications and structural predictions
Previously published works on phage lysins against Gram-negative bacteria (46,
47) suggested that the C-terminal portions of the lysins might destabilize the bacterial
outer membrane to facilitate access to the peptidoglycan which is the lysin’s substrate
(Figure 2.1). Specifically, the highly cationic C-terminal region of A. baumannii phage
lysin LysAB2 was speculated to be involved in permeabilizing the outer membrane (46).
A similar highly positively charged sequence was identified in one of A. baumannii
phage lysins isolated in our laboratory. This peptide was named P307, and it extends
from amino acids 108-138 in PlyF307 (47), and resembles the LysAB2 peptide in terms
of length and charge, but sharing only 41.2% similarity and 17.6% identity (MacVector
ClustalW alignment).
P307 was modified with the eight amino acids constituting the full C-terminal part
of native PlyF307, forming peptide P307AE-8. In addition, eight amino acids
(SQSRESQC) were fused to the C-terminus of P307 to yield P307SQ-8C. This
modification was based on the observation of an earlier study showing that the lack of
these eight amino acids reduces the activity spectrum of the antimicrobial peptide HBc
ARD (52) against Gram-negative bacteria. Two additional modifications of P307SQ-8C
were also generated by: scrambling the sequence of the last eight amino acids to
CSQRQSES (P307CS-8); and changing the last amino acid from C to A (P307SQ-8A). The
sequence was scrambled to evaluate the importance of a specific sequence and the
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cysteine change was introduced to examine the importance of intermolecular disulfide
bond formation for activity. The amino acid sequences of the peptides are summarized in
Table 2.1.
The structures of PlyF307 and P307SQ-8C were predicted by I-TASSER server
(Zhang Lab, University of Michigan) (58-60) and the helical wheel plot for P307SQ-8C
was created by NetWheels web application (61).

Figure 2.1 Permeabilization of outer membrane by Gram-negative lysin.
The cluster of positively charged amino acids at the C-terminus has been hypothesized to
allow the lysin to traverse the outer membrane to reach the peptidoglycan. Upon contact
with the peptidoglycan, the catalytic domain cleaves specific bonds resulting in hypotonic
lysis and death. Adapted by permission from Portland Press: Biochemical Society
Transactions (62), copyright 2016.
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Table 2.1 Peptide derivatives of PlyF307
Names

Amino acid sequences

PlyF307

146 amino acids (GenBank Accession Number KJ740396)

P307

NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRK (108th-138th)

P307AE-8

NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRKAEMELFLK (original)

P307SQ-8C

NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRKSQSRESQC (from Hep B)

P307CS-8

NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRKCSQRQSES (scramble)

P307SQ-8A

NAKDYKGAAAEFPKWNKAGGRVLAGLVKRRKSQSRESQA (C39A)

2.1.1.2 Synthesis
Peptides were synthesized at The Rockefeller University Proteomics Resource
Center. All peptides were created using a Protein Technologies Symphony™ peptide
synthesizer (PTI Tucson, Arizona, USA) on pre-coupled Wang (p-alkoxy-benzyl alcohol)
resin (Bachem, Torrance, CA, USA). Reaction vessels were loaded at 25 µM and
peptides were elongated using Fmoc protected amino acids (Anaspec, San Jose, CA,
USA) (63). Deprotection of the amine was accomplished with 20% piperidine (SigmaAldrich) in NMP (N-methylpyrrolidinone). Repetitive coupling reactions were conducted
using 0.6 M HATU/Cl-HOBT (azabenzotriazol tetramethyluronium
hexafluorophosphate/6-chloro-1-hydroxybenzotriazole)(P3 Biosystems, Shelbyville, KY,
USA) and 0.4 M NMM (N-methylmorpholine) using NMP (EMD) as the primary solvent
(64). Resin cleavage and side-chain deprotection were achieved by transferring to a 100
mL round bottom flask and reacted with 4.0 mL concentrated, sequencing grade,
trifluoracetic acid (Fisher) with triisopropylsilane (Fluka), degassed water, and 3,6-dioxa1,8-octanedithiol (DODT, Sigma-Aldrich) in a ratio of 95:2:2:1 over a 6 h time frame.
This was followed by column filtration to a 50 mL round bottom flask and TFA volume
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reduced to 2 mL using a rotary evaporator. A standard ether precipitation was performed
on the individual peptides by transferring to a 50 mL falcon tube containing 40 mL cold
tert-butyl methyl ether (TBME, Sigma-Aldrich). Samples were placed in an ice bath for 2
h to aid precipitation followed by pellet formation using centrifugation (3300 rpm, 5
min). Excess ether was removed by vacuum aspiration and the peptide pellets were
allowed to dry overnight in a fume hood. Dried peptide pellets were resolved in 20%
acetonitrile and 10 mL HPLC grade water, subsampled for LC/MS and lyophilized. All
crude products were subsequently analyzed by reverse-phase Aquity™ UPLC (Waters
Chromatography, Milford, MA, USA) using a Waters BEH C18 column. Individual
peptide integrity was verified by tandem electrospray mass spectrometry using a
ThermoFinnigan LTQ™ (Thermo Fisher, Waltham, MA, USA) spectrometer system.
Preparative chromatography was accomplished on a Vydac C18 RP preparative column
on a Waters 600 Prep HPLC. Individual fractions were collected in 30 s intervals,
characterized using LC/MS and fractions containing desired product were lyophilized.
These were stored at -20°C until being re-suspended in autoclaved Milli-Q water for
various assays. The stock solutions were then stored at 4°C.
2.1.2 Activity
2.1.2.1 Bacterial strains and growth conditions
A. baumannii strains in this study include clinical isolates from Hospital for
Special Surgery in New York (#1775-#1799) (47), Ohio State University (S1, S3 and S5
provided by Dr. Vijay Pancholi), and ATCC® 17978™ from American Type Culture
Collection. Bacteria were cultured in Trypticase Soy Broth or Brain Heart Infusion (TSB
or BHI; Thermo Fisher Scientific, Waltham, MA, USA) at 37°C with aeration (200 rpm).
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Stationary phase bacteria were cultured overnight while log phase bacteria were grown
for 3 h in fresh media from 100x dilutions of overnight cultures. Strains for determining
the specificity of the antimicrobial peptides were cultured under the same conditions, at
the temperatures indicated: B. anthracis ΔSterne (30°C), E. coli DH5α (37°C), K.
pneumoniae ATCC® 700603TM and 10031TM (37°C), P. aeruginosa PAO1 (30°C), and S.
aureus RN4220 (30°C).
Biofilms were set up as previously described (47). Briefly, an overnight culture of
A. baumannii strain #1791 was diluted 1000x (~105 cfu/mL) in TSB containing 0.2%
glucose and incubated at 37°C for 72 h in ~2.5 cm segments of PVC catheter tubing
(CareFusion) with the ends clamped shut to prevent evaporation. The catheter biofilms
were washed with autoclaved Milli-Q water to remove planktonic cells before peptide
treatment. Crystal violet (0.1%) was used to detect the presence of biofilm.
2.1.2.2 Bactericidal assays
Unless otherwise indicated, stationary phase bacteria (overnight cultures) were
used for the assays. Bacteria were washed in assay buffer, re-suspended to ∼106 cfu/mL,
mixed with each antimicrobial peptide and incubated for 2 h at room temperature (2225°C). After treatment, the reactions were serially diluted and plated for enumeration.
Influencing factors on the activities of the peptides (P307 and P307SQ-8C) were examined:
buffer (50 mM sodium phosphate or Tris-HCl, pH 6.8-8.8; NaCl (0-200 mM);
concentration (0-125 µg/mL P307); time (1-120 min); specificity (the bacterial strains
mentioned above); and growth phase (log, stationary and biofilm). The buffer system for
the experiments with the latter five factors was 50 mM Tris-HCl, pH 7.5. The biofilmassociated bacteria were re-suspended by thoroughly scraping the catheter tubing and
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vortexing for 1 min. Experiments were conducted at least in triplicate and representative
data are shown as mean + standard deviation. The black horizontal lines mark the limit of
detection.
2.1.2.3 MIC, resistance and synergy assays
The broth microdilution method was used (65) to determine the MICs of
levofloxacin, ceftazidime, polymyxin B, P307 and P307SQ-8C for A. baumannii strains
#1791, #1798, S5 and ATCC17978. For the antibiotics, 1.5–2 fold serial dilutions (three
lower and three higher) of the MICs determined by Etest (47) were included. For the
peptides, two-fold serial dilutions (2000–31.25 µg/mL) were tested. Overnight cultures
were re-suspended to ~105 cfu/mL in Mueller Hinton broth (pH 7.9). Antibiotics or
peptides were added to a final volume of 100 µL for each dilution. Bacteria were allowed
to grow at 37°C for 24 h at 220 rpm. The absorbance at 595 nm was then read in a
SpectraMax Plus Reader (Molecular Devices). The MICs were determined as the lowest
concentrations of antimicrobial agents that visibly inhibited bacterial growth. In addition,
Alamar®Blue was used to confirm the data obtained from OD595. Each experiment was
repeated at least twice in duplicate.
Resistance development was investigated for P307, P307SQ-8C and polymyxin B
with modifications to a published protocol (37). Briefly, A. baumannii strain #1791 was
grown in two-fold serial dilutions (0.25× to 2× MIC) of the antimicrobial agents. The
cultures commenced with 105 cfu/mL in MH broth (pH 7.9) as described above. The next
day, each thriving culture in the highest concentration well was taken through the process
again with two-fold serial dilutions (0.25× to 2× MIC) of respective antimicrobial agents
and 105 cfu/mL starting culture. The process was repeated 7 times.
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To investigate whether synergy exists between each peptide and antibiotic,
checkerboard assays were conducted by mixing fractional inhibitory concentrations
(FICs) of antibiotics (levofloxacin, ceftazidime and polymyxin B) with those of peptides
P307 and P307SQ-8C as previously described (66). Isobolograms were constructed to
determine the fractional inhibitory concentration indices (FICIs). Each experiment was
repeated at least three times.
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2.2

RESULTS

2.2.1 Structural analyses of peptides
The predicted structures of PlyF307 and P307SQ-8C suggested that the peptides
form a “hairpin-like” di-alpha helical structure connected with a flexible linker region
and the helical wheel plot suggested an amphipathic helix motif (Figure 2.2).

Figure 2.2 Structural analyses.
Predictions of (A) PlyF307 and (B) P307SQ-8C by I-TASSER server (58-60). (C) Helix
wheel plot of P307SQ-8C by NetWheels web application (61).
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2.2.2 Activity
2.2.2.1 Bactericidal assays
First the bactericidal activities of the peptides P307, P307AE-8 and P307SQ-8C were
compared. P307SQ-8C was the most active, reducing ~106 cfu/mL of bacteria to below the
limit of detection (<10 cfu/mL). P307 was slightly more active than P307AE-8, but both
peptides induced ~3.8-log decreases in viability (Figure 2.3A). Since P307SQ-8C was the
most active, the importance of the last eight amino acids SQSRESQC was investigated.
To test whether the linkage between P307 and the eight-amino-acid peptide was
important, the activities were compared among P307, P307SQ-8C, the combination of P307
and equimolar concentrations of the SQSRESQC peptide and the SQSRESQC peptide
alone. The combination was only as active as P307 while the SQSRESQC peptide alone
had no activity (Figure 2.3B). Hence the linkage was essential for the high bactericidal
activity of P307SQ-8C. Next, the importance of sequence and composition was investigated
by synthesizing P307CS-8 with the last eight amino acids in P307SQ-8C scrambled to
CSQRQSES. The bactericidal activities of P307SQ-8C and P307CS-8 were comparable
(Figure 2.3C), indicating that the amino acid composition was more important than the
sequence for the superior activity of P307SQ-8C. For further investigation, we used P307SQ8C

since it was the most active, and compared its activity to P307.
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Figure 2.3 Comparison of in vitro
bactericidal activities of peptides.
Bacteria were treated with 50 µg/mL
of each peptide for 2 h at 22-25°C.
Serial dilutions were plated for cfu
counting. (A) The bactericidal
activities of P307 and its variants
P307AE-8 and P307SQ-8C against A.
baumannii strains #1791, S5 and
ATCC17978. (B) The activities of
P307, P307SQ-8C, and equimolar
SQSRESQC peptide with and without
P307 against strains #1791 and S5.
(C) The activities of P307SQ-8C and a
scramble variant P307CS-8 against
strains #1791, S5 and ATCC17978.
The error bars show standard
deviation and the black horizontal
line marks the limit of detection.
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The effects of pH and NaCl on the in vitro activities of P307 and P307SQ-8C were
investigated. A. baumannii strain #1791 was treated with 50 µg/mL of either peptide in
the presence of varying pH and salt conditions. Using two buffer systems (sodium
phosphate and Tris-HCl), pH 6.8, 7.5, 8.0 and 8.8 were compared. The peptides were
more active in Tris-HCl buffer and higher pH values elicited better killing (Figure 2.4A).
Thus, the in vitro experiments were continued with 50 mM Tris-HCl, pH 7.5 to
approximate physiological pH. The activities of both peptides were inversely
proportional to the concentration of NaCl (Figure 2.4B). When titration and killing
kinetics were investigated, the activities of both peptides were concentration-dependent
(Figure 2.4C) and P307SQ-8C acted faster than P307, resulting in ~3.2-log decrease after 5
min, with a continued reduction in bacterial count up to ~5 logs 120 min after P307SQ-8C
addition (Figure 2.4D). There was no difference in activities of both peptides either at
room temperature (22-25°C) or 37°C and they retained activity after being heated at 95ºC
for 1 h (data not shown). From these in vitro characterization experiments, the optimal
experimental conditions were chosen to be 50 µg/mL peptides in 50 mM Tris-HCl, pH
7.5 for 2 h at 22-25°C, unless otherwise indicated.
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Figure 2.4 In vitro bactericidal activities of P307 and P307SQ-8C.
A. baumannii strain #1791 was treated with 50 µg/mL of P307 or P307SQ-8C for 2 h at 2225°C to investigate the optimal (A) pH and (B) NaCl concentration for killing. The same
conditions, except for the variables, were used with 50 mM Tris-HCl, pH 7.5 to
determine the (C) optimal killing concentration, and (D) killing kinetics. The error bars
show standard deviation and the black horizontal line marks the limit of detection.
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The in vitro bactericidal spectra of P307 and P307SQ-8C were also examined.
Among the bacteria tested, A. baumannii strains were consistently the most sensitive to
the peptides, showing an average of 2.7- and 6.2-log decrease with P307 and P307SQ-8C,
respectively. Bacillus anthracis, Pseudomonas aeruginosa and Staphylococcus aureus
were moderately sensitive to P307 and P307SQ-8C, with an average of ~1.3- and 2.9-log
decrease, respectively. Both E. coli and Klebsiella pneumoniae were resistant to the
peptides under these experimental conditions (Figure 2.5).
To examine the activity of each peptide against A. baumannii at different growth
phases, the sensitivities of strain #1791 were compared at log phase, stationary phase and
in biofilms. The log phase organisms were slightly more sensitive to P307 than stationary
phase (~3.7- versus 2.4-log decrease) (Figure 2.6A). However, no such difference was
observed for P307SQ-8C, with both growth phases being equally sensitive to the maximal
killing effect of the P307SQ-8C (>5-log decrease). Biofilm-associated A. baumannii was
more resistant (Figure 2.6B). Biofilms were treated with 250 µg/mL P307 or P307SQ-8C
for 2 or 24 h. After 2 h, ~3- and 4-log decrease in cfu/mL was observed with P307 and
P307SQ-8C, respectively. After 24 h, an additional ~1.3-log decrease was observed with
P307 while there was no further decrease with P307SQ-8C.
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Figure 2.5 In vitro bactericidal spectra of P307 and P307SQ-8C.
Different bacterial species (A. baumannii, B. anthracis, E. coli, P. aeruginosa, S. aureus
and K. pneumoniae) were treated with 50 µg/mL of P307 or P307SQ-8C in 50 mM TrisHCl, pH 7.5 for 2 h at 22-25°C to investigate the specificity of the peptides. Serial
dilutions were plated for cfu counting. The error bars show standard deviation and the
black horizontal line marks the limit of detection.
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Figure 2.6 Bactericidal activities of P307 and P307SQ-8C against A. baumannii
strain #1791 in log phase, late-stationary phase and biofilm.
(A) Bacteria in log phase and late stationary phase were treated with 50 µg/mL of P307
or P307SQ-8C for 2 h at 22-25°C. (B) A. baumannii biofilms in PVC catheters were treated
with 250 µg/mL of P307 or P307SQ-8C for 2 or 24 h at 22-25°C. Serial dilutions were
plated for cfu counting. The error bars show standard deviation and the black horizontal
line marks the limit of detection.
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2.2.2.2 MIC, resistance and synergy assays
In order to compare the efficiency of the peptides with clinically used antibiotics,
minimal inhibitory concentration (MIC) assays were performed on four A. baumannii
strains: #1791, #1798, S5 and ATCC17978. The strains displayed varying degrees of
sensitivity to levofloxacin, ceftazidime and P307 while the MICs of polymyxin B and
P307SQ-8C were more consistent (Table 2.2). P307SQ-8C had a lower MIC than P307,
which was in accordance with in vitro killing activity (Figure 2.3 and 2.5).
No resistance was observed for any of the antimicrobial agents. However since
the starting culture was 105 cfu/mL, it is likely that the frequency of resistant clone
development was not high enough to be detected.
The synergistic effects were examined between each peptide and levofloxacin,
ceftazidime or polymyxin B by the checkerboard method (isobologram). No synergy was
observed between either peptide and levofloxacin or ceftazidime (data not shown).
However, polymyxin B acted synergistically with both P307 and P307SQ-8C (FICIs =
0.125, <0.5).
Table 2.2 MIC comparison of peptides and antibiotics examined in this study
A. baumannii

Levofloxacin

Ceftazidime

Polymyxin B

strains

µg/mL

µM

µg/mL

µM

µg/mL

µM

µg/mL

µM

µg/mL

µM

#1791

6

16.6

128

234

0.25

0.19

750

221

62.5

14.5

#1798

32

88.6

>1024

>1873

0.25

0.19

1000

294

62.5

14.5

S5

6

16.6

64

117

0.25

0.19

2000

588

125
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ATCC17978

0.075

0.21

6

11

0.25

0.19

750

221

125
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P307

P307SQ-8C
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3

CHAPTER 3 – INFLUENCING FACTORS ON BACTERICIDAL
ACTIVITIES

3.1

MATERIALS AND METHODS

3.1.1 Inter-peptide disulfide bond formation
The contribution of disulfide bond formation to the increased activity of P307SQ-8C
was investigated by comparing with P307SQ-8A in the presence of the reducing agent
TCEP (0.1 and 1 mM) (Tris (2-carboxyethyl) phosphine hydrochloride solution)(Sigma).
Experiments were conducted at least in triplicate and representative data are shown as
mean + standard deviation.
3.1.2 pH-dependent sensitivity of E. coli and K. pneumoniae
The least sensitive Gram-negative species at pH 7.5 (Figure 2.5) were treated with
50µg/mL P307 or P307SQ-8C at pH 8.8. Experiments were conducted at least in triplicate
and representative data are shown as mean + standard deviation. The black horizontal line
marks the limit of detection.
3.1.3 DNA-binding assay
The affinity of peptide P307 for DNA was investigated by electrophoretic
mobility shift assay (67). P307 was mixed with 50 ng of random DNA (1 kb amplicon of
Bdellovibrio genomic DNA) at different peptide to DNA ratios (0:1-15:1) in a binding
buffer (5 mM Tris-HCl, pH 8.0, 10 mM EDTA, 5% glycerol, 20 mM KCl, 50 µg/mL
BSA). As a positive control, a peptide from Bdellovibrio bacteriovorus that was
previously found in our laboratory to have DNA-binding capacity (amino acid sequence –
MASKTKKTEYIRERKKATSGKKRKAANRTKGTTKSAKTLFKD) was used
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(unpublished results). After incubation for 1 h at 22-25°C, the peptide and DNA mixture
was analyzed by Agarose gel electrophoresis (67).
3.1.4 Transmission electron microscopy (TEM)
An overnight culture of A. baumannii strain #1791 was collected, washed in 50
mM Tris-HCl, pH 7.5 and re-suspended in the same buffer to ~108 cfu/mL. The bacteria
were treated with buffer (control) or 300 µg/mL P307SQ-8C or 1 mg/mL lysozyme (from
chicken egg white, lyophilized powder, protein ≥90%) (Sigma) or 300 µg/mL P307SQ-8C
and 1 mg/mL lysozyme combined for 5 min or 2 h. The samples were fixed with 2.5%
glyceraldehyde in 0.1 M sodium cacodylate, and then TEM images were taken at
magnification ×3300 or ×6600. Representative figures are shown.
3.1.5 SYTOX green uptake assay
The permeability of bacterial membrane upon peptide treatment was measured by
SYTOX® Green uptake (52). Briefly, overnight cultures of bacteria were washed and resuspended to ∼107 cfu/mL in 50 mM Tris-HCl pH 7.5. Benzonase® nuclease (25
U/mL)(Novagen) and SYTOX® Green (1 µM)(Invitrogen) was added to the bacterial
cells, and incubated for 15 min at 22-25°C in the dark. Peptides (50 µg/mL; 14.7 µM
P307 and 11.6 µM P307SQ-8C) were added. Polymyxin B (2 µg/mL)(Sigma) was used as a
control (68). Relative fluorescence units (RFU) were measured in a SpectraMax Plus
reader (Molecular Devices) at 22-25°C (ex: 485 nm, em: 520 nm) for 2 h. Experiments
were carried out twice in duplicate and representative data are shown as mean ± standard
deviation.
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3.2

RESULTS

3.2.1 Inter-peptide disulfide bond formation
Since P307SQ-8C contained a C-terminal cysteine, the importance of disulfide bond
formation for the high activity of P307SQ-8C was investigated. SDS-PAGE analysis
showed that a portion of P307SQ-8C (~5-10%) ran at twice the theoretical molecular
weight (MW) of this peptide while all of P307SQ-8A ran at the theoretical MW (data not
shown), suggesting a role for disulfide bond formation. To examine this, the C-terminal
cysteine residue of P307SQ-8C (the only cysteine in this peptide) was changed to alanine.
The resulting alanine variant, P307SQ-8A, ran at the expected size for a peptide monomer
(4.3 kDa) with no observable band at the dimer location by SDS-PAGE (data not shown).
The difference in bactericidal activities of P307SQ-8A and P307SQ-8C were compared within
the limit of detection by using 10 µg/mL peptides instead of 50 µg/mL. Furthermore,
TCEP (0.1 and 1 mM) was added to specifically reduce disulfide bonds. Without TCEP,
P307SQ-8C was more active than P307SQ-8A (~5- versus ~2.7-log decrease) (Figure 3.1).
The addition of TCEP did not affect P307SQ-8A while the activity of P307SQ-8C was
reduced by ~2 logs. However, P307SQ-8A was still more active than P307, suggesting that
although disulfide bond formation was important, it was not the only contributing factor
for the superior activity of P307SQ-8C.
3.2.2 pH-dependent sensitivity of E. coli and K. pneumoniae
Among the Gram-negative species examined, E. coli and K. pneumoniae were the
least sensitive to the peptides at pH 7.5 (Figure 2.5). However, at pH 8.8, both were
sensitive to 50 µg/mL of the peptides (Figure 3.2), indicating the electrostatic interactions
between the peptides and bacterial membrane.
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Figure 3.1 The importance of terminal cysteine and its disulfide bond
formation for bactericidal activity of P307SQ-8C.
A. baumannii strain #1791 was treated with 10 µg/mL P307SQ-8A (with Ala instead of Cys
at the C-terminus) or P307SQ-8C in 50 mM Tris-HCl, pH 7.5 with or without TCEP for 2 h
at 22-25°C. Serial dilutions were plated for cfu counting. The error bars show standard
deviation.
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Figure 3.2 Bactericidal activities of P307 and P307SQ-8C against K.
pneumoniae and E. coli at pH 7.5 and 8.8.
The bacteria were treated with 50 µg/mL peptides in 50 mM Tris-HCl for 2 h at 22-25°C.
Serial dilutions were plated for cfu counting. The error bars show standard deviation and
the black horizontal line marks the limit of detection.
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3.2.3 DNA-binding assay
Due to the presence of several cationic residues on the peptides (net charge of
+7), their effects on DNA were investigated. The affinity of P307 for DNA was
examined by electrophoretic mobility shift assay. There was no shift in molecular weight
at all ratios of P307 to DNA tested whereas a positive control peptide known to bind
DNA caused a clear shift in electrophoretic mobility (Figure 3.3).

Figure 3.3 Affinity of P307 for DNA.
The peptide P307 was mixed with DNA at different peptide:DNA ratios (0:1-15:1) and
incubated for 1 h before being analyzed on an Agarose gel. In comparison to positive
control peptide, no electrophoretic shift was observed for P307.
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3.2.4 Transmission electron microscopy (TEM)
Another negatively charged bacterial component investigated was bacterial
membrane. TEM was used to visualize the effects of P307SQ-8C on A. baumannii
membrane. The samples were prepared by treating A. baumannii strain #1791 with buffer
(control) or 300 µg/mL P307SQ-8C or 1 mg/mL lysozyme or peptide and lysozyme
combined for 5 min or 2 h. A comparison of the TEM images revealed that treatment
with P307SQ-8C led to: 1) membrane blebbing and changes in intracellular density, 2)
appearance of ‘intact bacterial ghosts’, and 3) occasional disruption of the cell wall and
cytoplasmic membrane (Figure 3.4A, B and C). On the other hand, lysozyme hydrolyzed
the peptidoglycan and released the cellular content (Figure 3.4D). Finally, the combined
treatment resulted in complete debris formation as P307SQ-8C and lysozyme destabilized
the membrane and peptidoglycan simultaneously (Figure 3.4 E and F).
3.2.5 SYTOX green uptake assay
As our data suggested a killing mechanism by cytoplasmic membrane
destabilization, the extent of bacterial membrane disruption by P307 and P307SQ-8C was
measured using the SYTOX® Green uptake assay. Both peptides permeabilized the
membranes of A. baumannii strain #1791 at pH 7.5 and K. pneumoniae strain
ATCC700603 at pH 8.8, giving rise to an increase in fluorescent signals of SYTOX®
Green dye as it bound to intracellular DNA. In contrast, the signal increase was minimal
for K. pneumoniae ATCC700603 at pH 7.5 (Figure 3.5). The results were consistent with
the difference in sensitivities of the bacterial species at different pH (Figures 2.5 and 3.2).
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Figure 3.4 Representative TEM images.
A. baumanii strain #1791: untreated control (A), treated with 300 µg/mL P307SQ-8C for 5
min (B) and for 2 h (C), treated with 1 mg/mL lysozyme for 2 h (D), treated with 300
µg/mL P307SQ-8C and 1 mg/mL lysozyme for 5 min (E) and for 2 h (F). Magnification, ×
3300 (left, scale bar = 1 µm) and ×6600 (right top and bottom, scale bar = 600 nm).
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Figure 3.5 Membrane permeability of bacteria treated with P307 and P307SQ8C.

A. baumannii strains #1791 and K. pneumoniae strain ATCC700603 were treated in 50
mM Tris-HCl at indicated pH with 50 µg/mL of P307 or P307SQ-8C in the presence of 1
µM SYTOX® Green (Invitrogen). Benzonase® nuclease (25 U/mL)(Novagen) was also
added to remove extracellular DNA. The permeability of bacterial membrane was
monitored for 2 h by the increase in relative fluorescence units of SYTOX® Green dye,
using polymyxin B as a positive control. The error bars show standard deviation.
3.3
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4
4.1

CHAPTER 4 – SAFETY AND IN VIVO ACTIVITY
MATERIALS AND METHODS

4.1.1 Cytotoxicity assays
The hemolytic assays were conducted as previously described (52). Briefly,
human blood was gathered in an EDTA-tube, and red blood cells (RBC) were collected
through low speed centrifugation. Cells were washed and re-suspended to a 10% RBC
solution in PBS, and mixed with 80 µM (345 µg/mL) P307SQ-8C. PBS and 1% Triton X100 were used as negative and positive controls, respectively. After 1 h incubation at
37°C, the supernatant was collected, and the absorbance at 405 nm was recorded through
SpectraMax Plus Reader (Molecular Devices) to measure the release of hemoglobin. The
reactions were carried out twice in triplicate and representative data are shown as mean +
standard deviation.
A human B lymphoblastoid cell line (LCL) obtained from The Rockefeller
University was grown in RPMI media supplemented with L-glutamine and 10% fetal
bovine serum. Cells were harvested by low speed centrifugation, washed and resuspended in PBS to ~5x106 live cells/mL, as determined by trypan blue exclusion tests.
LCL cells (~5x105) were incubated with 40, 80 and 120 µM P307SQ-8C at 37°C in a
humidified 5% CO2 atmosphere for one hour. The cells were then stained according to
manufacturer’s instructions (CellTiter 96 Non-radioactive cell proliferation assay,
Promega) where live B cells reduced the dye to insoluble formazan for an additional 4 h.
Solubilization/Stop solution was added and incubated at 37°C overnight. Next, the
absorbance at 570 nm was measured in SpectraMax Plus Reader (Molecular Devices) to
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quantitate B cell survival. Triton X-100 was used as a positive control. The reactions
were carried out in triplicate and data are shown as mean + standard deviation.
4.1.2 Endotoxin assay
To detect the amount of endotoxin release, strain #1791 (~107 cfu/mL) was
incubated at 22-25°C for 2 h with different concentrations of P307 or P307SQ-8C. The
samples were briefly centrifuged (2000 × g) for 1 min to remove live cells. All reagents
were prepared in endotoxin-free autoclaved Milli-Q water. Endpoint Chromogenic LAL
Assay (Lonza) was conducted according to manufacturer’s instructions. Polymyxin B and
100% ethanol were used for comparison and positive control, respectively. The
experiment was conducted twice in duplicate and representative data are shown as mean
+ standard deviation.
4.1.3 Bactericidal activity in plasma and its components
Human blood was collected in a heparin-tube and centrifuged. The supernatant
was filtered and stored at 4°C overnight. The filtrate was centrifuged and filtered again to
remove any debris. The resulting solution was used as 100% plasma. The components of
plasma examined for interference were monovalent cation (Na+), divalent cations (Ca2+
and Mg2+) and albumin. Chloride salts of the cations and albumin from human serum
(lyophilized powder, ≥ 97%)(Sigma) were prepared in Milli-Q water and sterile filtered.
Bactericidal assays, as described above, were conducted in 100% plasma, and in buffered
solutions (50 mM Tris-HCl, pH 7.5) containing 150 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, and 50 mg/mL human serum albumin (HSA), using 100 µg/mL P307 or P307SQ8C.

The experiments were conducted at least in triplicate and data are shown as mean +

standard deviation.
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4.1.4 Mouse skin infection
The Rockefeller University institutional animal care and use committee approved
all in vivo protocols. Skin infection was induced with A. baumannii as previously
described (69). Briefly, the backs of 30 female CD-1 mice (6 to 8 weeks of age; Charles
River Laboratories) were shaved with an electric razor. NairTM depilatory cream was
applied to the shaved areas to remove any remaining hair. The areas were then
disinfected with alcohol wipes, and tape stripped with autoclave tape 20 times in
succession, using a fresh piece of tape each time. The tape stripped areas were disinfected
again with alcohol wipes. An area of ~ 1 cm2 was then marked and infected with 10 µL
of ~108 cfu/mL A. baumannii strain #1791. The bacteria were allowed to colonize for 1618 h, after which the infected area was either left untreated or treated with 200 µg of
P307SQ-8C or 2 µg of polymyxin B in autoclaved Milli-Q water for 2 h. To harvest the
remaining bacteria on the skin, the mice were sacrificed and the infected skin was
processed in 500 µL PBS for 1-2 min in a Stomacher® 80 Biomaster using a microbag
(Seward Ltd., UK). The solution was serially diluted and plated on LB agar containing 4
µg/mL levofloxacin and 12 µg/mL ampicillin for selection. The resulting cfu/mL from
each animal was plotted as an individual point and the horizontal bars represent the mean
values. Data were analyzed using Ordinary one-way ANOVA in GraphPad Prism 6.0.
The dotted horizontal line marks the limit of detection.
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4.2

RESULTS

4.2.1 Cytotoxicity assays
Since membrane-acting antimicrobial peptides have been shown to be active
against mammalian membranes (70), the cytotoxicity of the peptides were evaluated
using human red blood cells (RBCs) and B cells. In contrast to the 1% Triton-X-100
positive control, 80 µM (345 µg/mL) P307SQ-8C did not lyse RBCs but killed A.
baumannii strain #1791 (~4.8 logs) in PBS (Figure 4.1A). Similarly, the survival of B
cells was not significantly affected by 40, 80 and 120 µM P307SQ-8C (Figure 4.1B).
4.2.2 Endotoxin assay
Even though the peptides did not display cytotoxicity against human RBCs,
toxicity could possibly arise from the bacterial endotoxin released upon peptide
treatment. Hence, the Endpoint Chromogenic LAL Assay (Lonza) was conducted to
measure the amount of endotoxin released by A. baumannii strain #1791 after 2 h of
incubation with peptides. The peptides generated endotoxin unit concentrations similar to
that of the 100% ethanol positive control. Polymyxin B released more endotoxin at 0.5
µg/mL than at 2 µg/mL, but less than the peptides (Figure 4.2). This apparent reduced
release was likely due to the known interaction of polymyxin B with lipid A (71), the
active component for LAL assay. The peptides did not interfere with endotoxin detection
(data not shown).
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Figure 4.1 Cytotoxicity assays.
(A) Hemolysis. Red blood cells (RBCs) were incubated with 345 µg/mL P307SQ-8C in
PBS and the release of hemoglobin into the supernatant was measured by OD405 to
determine hemolysis, using 1% Triton X-100 as a positive control. The activity of
P307SQ-8C was examined against A. baumannii strain #1791 under the same experimental
conditions. (B) B cell survival. Live B cells (~5x105) were incubated with 172.5, 345 and
517.5 µg/mL P307SQ-8C for 1 h at 37°C in a humidified 5% CO2 atmosphere. CellTiter
96® Non-Radioactive Cell Proliferation Assay (Promega) was conducted to quantify the
survival of B cells, using 1% Triton X-100 as a positive control. The error bars show
standard deviation and the black horizontal line marks the limit of detection for cfu/mL.

48

Figure 4.2 Endotoxin release.
A. baumannii strain #1791 (~107 cfu/mL) was treated with different concentrations of
antibacterials for 2 h at 22-25°C. The samples were centrifuged to remove live cells. The
supernatant was analyzed with the Endpoint Chromogenic LAL Assay (Lonza) to
measure endotoxin units, using 100% ethanol as a positive control. The error bars show
standard deviation and the black horizontal line marks the limit of detection for cfu/mL.
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4.2.3 Bactericidal activity in plasma and its components
The activities of the peptides were examined in human blood plasma. Both P307
and P307SQ-8C (100 µg/mL) were inactive in 100% plasma. The activities in Tris buffer
were also interfered to varying degrees by the addition of monovalent and divalent
cations as well as human serum albumin at physiological concentrations (Figure 4.3).
4.2.4 Mouse skin infection
Since blood plasma interfered with the activities of both peptides, and the skin is a
common route of infection by A. baumannii, the in vivo activity of P307SQ-8C was
investigated using a mouse skin infection model. Skin abrasions were induced on the
shaved backs of the mice by tape-stripping, and the irritated skin was infected with 106
cfu of A. baumannii strain #1791 for 16 h. The infected area was then treated with 2 µg
polymyxin B or 200 µg P307SQ-8C for 2 h after which the infected skin was excised and
processed for bacterial counts. Both treatments were found to significantly reduce the
bacterial load (~2 logs) in the infected skin using this single dose (P < 0.02, Ordinary
one-way ANOVA) (Figure 4.4).
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Figure 4.3 Activities of peptides in plasma and its components.
A. baumannii strain #1791 was treated with 50 µg/mL P307 or P307SQ-8C for 2 h at 2225°C in 100% plasma or indicated concentrations of chloride salts of sodium, calcium
and magnesium and human serum albumin in 50 mM Tris-HCl, pH 7.5. Serial dilutions
were plated for cfu counting. The error bars show standard deviation and the black
horizontal lines mark the limit of detection for cfu/mL.
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Figure 4.4 In vivo activity of P307SQ-8C versus that of polymyxin B on tapestripped mice infected with A. baumannii strain #1791.
Topical treatments included no treatment (negative control), 2 µg polymyxin B (1.5
nmol) and 200 µg P307SQ-8C (46.5 nmol) for 2 h. The bars show the mean values and
each dot represents one mouse. Statistically significant differences were noted for the
comparison pairs: negative control and polymyxin B (P = 0.0148) and negative control
and P307SQ-8C (P = 0.0157), with ~2-log-drop in A. baumannii by each treatment
(Ordinary one-way ANOVA, Multiple comparisons, Uncorrected Fisher’s LSD test). The
dotted line marks the limit of detection.
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5
5.1

CHAPTER 5 – DISCUSSION
Lysin-based antimicrobial peptides

5.1.1 Sequence and structure
The antimicrobial peptides in this study (Table 2.1) were designed by observing
the ‘activity-contributing’ parts of phage lysins PlyF307 (47) and LysAB2 (46) and an
antimicrobial peptide HBc ARD (52). PlyF307 was found to be the most active among
the 21 distinct lysins isolated by screening a genomic library of prophages that were
induced from 13 A. baumannii strains. Instead of the domain structures typical of lysins,
PlyF307 comprises a single lysozyme domain and a C-terminus that has unusually high
positive net charge (+7). The amino acids 108-138 of PlyF307 are also 41.2% similar and
17.6% identical to the amino acids 113-145 of LysAB2. In LysAB2, those amino acids
are essential and their deletion leads to 40% activity loss although they do not encompass
the active site of the enzyme. Considering the high activity of PlyF307, we synthesized
the 31 amino acids of PlyF307 as peptide P307 to investigate its stand-alone bactericidal
activity. In HBc ARD, the removal of the last 8 amino acids (SQSRESQC) diminishes its
activity against S. aureus. In the hope of enhancing P307 activity, P307SQ-8C was
designed by piecing together P307 and SQSRESQC. Lastly, P307AE-8 was constructed to
compare the original extension AEMELFLK of PlyF307 to P307SQ-8C extension.
The structural predictions (58-60) of PlyF307 and P307SQ-8C revealed double
parallel helices joined by a loop for both P307AE-8 and P307SQ-8C. P307 was just a turn
and a half shorter. And the helices were amphipathic in nature according to the helical
wheel plot (61) (Figure 2.2). However, when the activities were compared, P307 and
P307AE-8 had similar activities while P307SQ-8C with its polar amino acids showed the
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highest bactericidal activity of all (Figure 2.3A). The addition of P307 and SQ-8C
extension separately did not achieve the same result as P307SQ-8C (Figure 2.3B) and the
extension by itself was inert. But scrambling the sequence to CSQRQSES in P307CS-8 did
not affect the bactericidal activity (Figure 2.3C). Although we tested only 1 out of 40,320
permutations, comparable killing activities by P307SQ-8C and P307CS-8 did suggest that the
8 amino acids could be arranged in an alternate order.
5.1.2 In vitro activity
The in vitro activity assays of P307 and P307SQ-8C were conducted with clinical
isolates to examine their antibacterial potential. Bactericidal assays showed that the
peptides are more active at higher pH (Figure 2.4A) and that P307SQ-8C acted faster than
P307, easily achieving >6-log-kill in 90 min (Figure 2.4D). They were specific to A.
baumannii with slight activities against B. anthracis, S. aureus and P. aeruginosa and no
activity against E. coli or K. pneumoniae at pH 7.5 (Figure 2.5). This selectivity towards
A. baumannii at pH 7.5 suggests that the outer layers of A. baumannii are more
negatively charged than those of the other bacterial species included in the assay since at
pH 8.8, the selectivity is nullified. They were also capable of killing biofilm-associated A.
baumannii albeit requiring higher concentrations (Figure 2.6B). However, their MICs
were much higher than that of polymyxin B (Table 2.2). It is possibly due to the
interference of cations in the growth media. More experimental data are required to
determine their susceptibility breakpoints, e.g. pharmacokinetics and pharmacodynamics
(72). Nevertheless, P307SQ-8C could be put to use for decontamination in clinical settings
because of its fast acting and biofilm killing properties. Since medical equipment and
furniture are important hospital reservoirs of A. baumannii (15, 16), P307SQ-8C could be
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used on these surfaces for quick bacterial removal. Moreover, catheter- and ventilatorassociated diseases are caused by the persistence of A. baumannii as biofilms (73), they
could be prevented by lining the surfaces with P307SQ-8C.
5.2

Mechanism of action
Biochemical characterizations of peptides-bacteria interactions have indicated the

target site to be the outer and inner membranes of A. baumannii. Higher pH in Tris buffer
elicited better killing activities of the peptides while higher salt concentrations lessened
their effectiveness (Figure 2.4A and B). Since Tris is a chemical substance known to
permeabilize membranes (74), it is not surprising that the peptides’ activities were higher
in Tris buffer than in phosphate buffer. However, it is notable that higher pH and fewer
cations promote killing. Even E. coli and K. pneumoniae that were resistant to the
peptides at pH 7.5 became susceptible to killing at pH 8.8 (Figure 3.2). Since the
theoretical isoelectric points of P307 and P307SQ-8C are 10.70 and 10.38, respectively,
their net charges should not alter at pH 7.5 and pH 8.8. Possibly the changes occur on the
bacterial membranes. In Gram-negative bacteria, the outer leaflet of the outer membrane,
being largely composed of polyanionic LPS, is stabilized by divalent cations (Ca2+ and
Mg2+) (75). At higher pH and lower salt concentrations, the positively charged peptides
could more easily establish ionic interactions with the outer membrane to permeate the
membranes and induce killing.
Further evidence by synergy, TEM and SYTOX green uptake assays also
supported the membrane permeabilization as the peptides’ mechanism of action. First, the
peptides exhibited in vitro synergy with polymyxin B whose membrane target is lipid A
of LPS (71). Among different possible mechanisms of synergy (76), the most likely
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scenario is the complementary actions from having the same target, i.e. both the
polymyxin B and the peptides killed the bacteria by permeabilizing the membrane in a
way that enhanced each other’s activity. The lack of synergy with levofloxacin and
ceftazidime suggested that DNA and cell wall were not the targets of the peptides.
Indeed, the DNA-binding assay showed that P307 did not bind to DNA (Figure 3.3).
Next, TEM images of A. baumannii treated with P307SQ-8C showed mostly intact bacterial
‘ghosts’ with altered cytoplasmic content (Figure 3.4B and C) as if the cytoplasm had
leaked out of the bacteria through the tiny holes punched by the peptide. In contrast, more
bacterial debris was formed by lysozyme that targets the peptidoglycan (Figure 3.4D).
During P307SQ-8C killing, the permeabilization of the inner membrane seemed to be the
limiting step because combined treatment with P307SQ-8C and lysozyme resulted in more
extensive debris formation. The outer membrane disruption of P307SQ-8C provided the
lysozyme access to the peptidoglycan and the lysozyme action preceded the inner
membrane disruption of P307SQ-8C. Lastly, the results from SYTOX green uptake assay
(Figure 3.5) confirmed that both outer and inner membranes were compromised by the
peptides to allow the inflow of SYTOX green dye.
However, the ability of the peptides to permeabilize bacterial membranes raises
the question of how their parent phage lysin PlyF307 is regulated by the phage during the
lytic cycle. The regulation of phage lysin is necessary to prevent pre-mature lysis of
bacteria before the production of phage progeny. Thus, there must be mechanisms in
place to prevent the positively charged region of PlyF307 disrupting the cytoplasmic
membrane from within the cell before the progeny are assembled. The peptide region
might be inhibited by structural conformation or temporal regulation or the non-optimal
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pH and salt conditions of the cellular environment. Future experiments with the phage
from which PlyF307 was isolated are necessary to clarify the regulation of PlyF307.
5.3

In vivo activity
The safety and efficacy of the peptides were investigated by hemolysis,

cytotoxicity, limulus amebocyte lysate (LAL) and plasma interference assays. First, the
hemolysis and B cell toxicity assays showed that the peptides did not lyse human red
blood cells and B cells. Although the peptides killed the bacteria by permeabilizing the
membranes, the mammalian membranes were spared. The cells remained viable at ~500
µg/mL of P307SQ-8C (Figure 4.1). Next, the LAL assay showed that the peptides released
endotoxins upon killing the bacteria. The amount released by P307SQ-8C was ~40 times
higher than that by polymyxin B (Figure 4.2) since the latter binds to lipid A and lowers
the level of detection. The released endotoxins could potentially initiate undesirable
inflammatory responses. Lastly, the bactericidal assay in plasma showed that the killing
activities of the peptides were interfered by plasma and its components such as
monovalent and divalent cations and serum albumin. The endotoxin release and plasma
interference together indicated that prophylactic use might not be feasible. Thus, mouse
skin infection model was selected to investigate the in vivo activity of P307SQ-8C. Using
200 µg of P307SQ-8C in distilled water, A. baumannii bacterial load on the irritated skin
surface was significantly reduced (~2-log-drop) (Figure 4.4), indicating that P307SQ-8C
could be used in topical applications.
5.4

Opportunities for improvement
Resistance development was not observed when selecting from 105 cfu/mL. Due

to material limitations, resistance evolutions at low frequency were not detected.
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Alternative experiments need to be conducted to better understand the potential of A.
baumannii developing resistance. For example, the MICs for colistin-resistant clones
should be determined and compared with non-resistant clones since colistin also
permeabilizes the membranes to kill the bacteria. Another option is to mutagenize A.
baumannii and screen for resistant clones.
Moreover, there are rooms for further development to achieve higher in vivo
activities even though the peptides are highly effective at killing A. baumannii in vitro.
Since disulfide bond formation contributes to the high activity of P307SQ-8C (Figure 3.1)
and only ~5-10% of the molecules are dimers, P307SQ-8C that forms permanent dimers
(e.g. with C-C bond in place of S-S bond between cysteines) might be designed by
incorporating unnatural amino acids. By changing the S-S bond to C-C bond, the
importance of disulfide bond formation versus that of dimer formation can also be
differentiated. For example, taking advantage of the peptides’ preference for high pH,
alkaline excipients can be used to achieve higher killing effect. However, a fine balance
needs to be maintained for high activity versus alkaline toxicity. Moreover, peptides can
be further engineered to be active in plasma. By using x-ray crystallography or NMR,
residues that interact with serum albumin can be deciphered and altered to minimize the
amount of peptides binding to the most abundant protein in plasma. The challenge in this
case is to achieve the goal without compromising the activity. Other strategies to improve
bioavailability include fusing P307SQ-8C to an antibody FC fragment (77) and creating
‘structurally nanoengineered antimicrobial peptide polymers’ (SNAPPs) (78) with
P307SQ-8C. By increasing the effective size of the peptide by FC fusion, the adsorption to
serum albumin could be reduced and FC fragment tag can also be recognized by FC
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receptors on immune cells. The bulkiness, however, can sterically interfere with the
peptide’s traversing the outer membrane to destabilize the inner membrane. Last, but not
least, SNAPPs are star-shaped polymers with multi-functional initiator poly(amidoamine)
PAMAM core that has 16 or 32 primary amines onto which antimicrobial peptides
(AMPs) are attached. The original version of SNAPPs with AMPs made up of poly lysine
and valine killed Gram-negative bacteria indiscriminately and had slight cytotoxic effects
at high concentrations. The efficacy was retained in the presence of serum despite
aggregate formation (78). Creating SNAPPs with P307SQ-8C can potentially increase the
in vivo activity of P307SQ-8C by effectively increasing the local concentrations 16 to 32
folds. In contrast to the original SNAPPs, P307SQ-8C SNAPPs might be more specific to
A. baumannii and less toxic to mammalian cells.
5.5

Potential practical uses
The pH dependence and salt intolerance might prevent broad in vivo application

but skin infections could be treated topically with the peptides. In addition, they could be
used in hospitals to decontaminate abiotic surfaces and eliminate reservoirs to prevent
future outbreaks as mentioned above.
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6

CHAPTER 6 – CONCLUSION
Due to the notable antibiotic resistance mechanisms of A. baumannii (29),

membrane-acting drugs like polymyxin B and colistin, with toxic side effects and rising
resistance, are now the last resort drugs (27). To address the A. baumannii threat, several
groups have evaluated the use of bacteriophage endolysins to kill multidrug-resistant A.
baumannii (42, 46, 47). It has been hypothesized that the innate bactericidal activities of
some of these lysins stem from the permeabilization of the bacterial outer membrane by
the highly positively charged C-terminal portions (46, 47). In this study, we showed that
P307, a C-terminal-based peptide from PlyF307 (47), by itself, had high in vitro
bactericidal activity (Figure 2.3A). Furthermore, we demonstrated that P307 could be
further engineered for log-fold increased activity. Compared to P307, or P307AE-8 with
the eight amino acids (AEMELFLK) constituting the full C-terminal part of native
PlyF307 (Table 2.1), the modified peptide P307SQ-8C with polar amino acids
(SQSRESQC) at the C-terminus was 10-15 times more active (Figure 2.5 and Table 2.2).
Comparison of P307SQ-8C to the scrambled P307CS-8 revealed that the 6 neutral and 2
charged polar amino acids (SQSRESQC) could be added in an alternate order for similar
activity (Figure 2.3C). Thus, while both AEMELFLK and SQSRESQC complete the
length of the alpha helix to correspond to the adjacent helix in the hairpin structure
(Figure 2.2), it is the characteristics of the amino acids in the SQSRESQC sequence (not
the structure) that dictate the increase in activity.
Both P307 and P307SQ-8C displayed high in vitro bactericidal activities. Not only
were they effective against numerous clinical isolates of A. baumannii (Figure 2.5) but
they also killed bacteria in biofilms on the surface of catheters (Figure 2.6B). Since the
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success of A. baumannii as an opportunistic pathogen is attributed to its improved
survival through biofilm formation and persistence in hospital environments (79), the
ability of the peptides to kill biofilm-associated bacteria could be harnessed to disinfect
hospital environments as well as to eliminate A. baumannii from the lumens of catheters
in situ. While the in vivo utility of the peptides might be limited due to the diminished
activity in plasma, the peptides could still be useful on abiotic surfaces such as coatings
for ventilators and catheters.
To further increase the potency of the peptides, we analyzed the mechanism of
action by various in vitro characterizations. The peptides were more active in higher pH
but did not tolerate salinity. E. coli and K. pneumoniae were resistant to the peptides at
pH 7.5 but were susceptible at pH 8.8 (Figure 2.5 and 3.2). Since the charges on the
peptide were not expected to vary as the pH changed from 7.5 to 8.8, we reasoned that
the changes likely occurred on the bacterial membrane. At higher pH, the bacterial
membrane can lose its cations, allowing the positively charged peptides to establish ionic
interactions to disrupt the membrane integrity. Based on these observations and data, we
postulate the following mechanism of action (Figure 6.1): P307SQ-8C establishes ionic
interactions with the bacterial outer and inner membranes, traversing the peptidoglycan
with its small size (4.3 kDa). In the process, the peptide disrupts both membranes (as
suggested by endotoxin release assay and shown by TEM images and SYTOX® Green
uptake assay) killing the cell. Assay with TCEP and P307SQ-8A also suggested that the
bactericidal activity was higher (by ~2-logs) when P307SQ-8C was dimerized. With this
knowledge base, we are currently exploring additional engineering strategies to further
improve both PlyF307 and P307SQ-8C.
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Figure 6.1 Proposed mechanisms of action.
When added externally the positively charged peptide P307SQ-8C disrupts the outer
membrane and traverses the peptidoglycan because of its small size. The peptide will
then disrupt the cytoplasmic membrane, resulting in hypotonic lysis and bacterial death.
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Nosocomial A. baumannii infections of deep wounds, burns and bone or bone
marrow are highly prevalent and the isolates are often multidrug resistant (17). Since one
of the common infection routes of A. baumannii is through damaged skin, we utilized an
already established skin infection model (69) for our in vivo characterization of P307SQ8C.

The backs of the mice were shaved and tape-stripped to create skin irritations, which

were then inoculated with 106 cfu of A. baumannii strain #1791. After 16 h of infection,
mice were topically treated with a single dose of 46.5 nmol P307SQ-8C or 1.5 nmol
polymyxin B. Both treatments significantly lowered the bacterial burden (~2-log
decrease) in the skin (Figure 4.4).
In conclusion, we engineered the positively charged C-terminal peptide P307
from the A. baumannii phage lysin PlyF307 for improved bactericidal activity. The
peptides exhibited high in vitro activities, and thus could potentially be utilized to control
A. baumannii on abiotic surfaces. The target of the peptides appeared to be the bacterial
membrane and the interaction likely occurred through electrostatic forces. Despite the
membrane target, the peptides did not lyse or kill human red blood cells and B cells.
Although body fluids and cations interfered with the activities of the peptides, P307SQ-8C
significantly decreased the bacterial cell count in a murine skin infection by A.
baumannii. We are currently investigating different designs to improve the activities of
the peptides as well as other phage lysins against A. baumannii.
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7

APPENDIX

7.1

Interesting observations

7.1.1 Anaerobic environment decreased bactericidal activities of P307 and P307SQ-8C
While investigating the peptides’ mechanisms of action, bactericidal experiments
were conducted in an anaerobic chamber to investigate the effect of oxygen. A.
baumannii strain #1791 was washed with and re-suspended in 50 mM Tris-HCl (pH 7.5
or pH 8.8) and treated with 50 or 200 µg/mL of P307 or P307SQ-8C at 37°C for 2 h
aerobically or anaerobically. Then the bacteria were serially diluted and plated on TSB
agar in respective oxygen environments. Afterwards the plates were incubated
aerobically since A. baumannii is strictly aerobic.
The bacteria became insensitive to the peptides at pH 7.5 and increasing the pH to
8.8 restored the sensitivities (Figure 7.1). The experiments were conducted twice in
triplicate. These results indicated that oxygen is necessary at lower pH to kill the bacteria
while at high pH, ionic interactions between peptides and membranes are strong enough
to kill the bacteria by disrupting the membranes without the need for oxygen. The oxygen
requirement at lower pH is interesting because it has been previously argued that
bacterial cell death by bactericidal antibiotics induced reactive oxygen species (ROS) (80,
81) and apoptotic pathway (82). Refuting these arguments, other research groups stated
that bacterial cell death induced by antibiotics does not depend on ROS formation, ROS
being the by-product of stress response (83, 84). Peptides requiring oxygen for
bactericidal effect seems to suggest the involvement of reactive oxygen species.
However, oxygen-dependent transport of the peptide across the outer membrane cannot
be completely ruled out. Using luminol and terephthalate has not been successful at
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detecting the ROS formation. Therefore, more experimental data are required to resolve
the issue. For example, ROS sensitive fluorescent dye, DCFDA (2',7'-dichlorofluorescin
diacetate) could be used for better ROS detection.

Figure 7.1 Bactericidal activities of the peptides in aerobic versus anaerobic
conditions.
A. baumannii strain #1791 was treated with 50 or 200 µg/mL P307 or P307SQ-8C for 2 h at
37°C in 50 mM Tris-HCl (pH 7.5 or 8.8) under aerobic or anaerobic conditions. Serial
dilutions were plated for cfu counting. The error bars show standard deviation and the
black horizontal lines mark the limit of detection.
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7.1.2 ATCC 17978 caused clearings on agar overlay containing DH5α
The surrounding area of A. baumannii strain ATCC 17978 colony was clear on an
agar overlay of E. coli strain DH5α (Figure 7.2). The clearing could be induced by
ATCC 17978 killing DH5α and the potential killing agents are phages, Type VI secretion
system and phage lysins.
Although most phages are strain specific, there also exist polyvalent phages that
infect more than one genus (85). The possibility was examined by plaque forming assay.
The prophages from ATCC 17978 were induced with mitomycin C and concentrated with
PEG-8000. The phage preparation was spotted on an agar overlay of DH5α, but no
plaque was observed. Most likely, phages were not involved in the killing.
A. baumannii has been shown to use type VI secretion system (T6SS) for bacterial
competition (86). This possibility has not been thoroughly examined but ATCC 17978
indeed possessed T6SS in its genome and deleting the essential components could reveal
whether T6SS is used for DH5α killing.
Last, but not least, phage lysins of Gram-negative bacteria have been shown to
perform non-phage related functions. For example, in Salmonella phage lysins are
retained from past infections and become orphan phage enzymes as indicated by the
difference in DNA composition in the up and downstream of the gene (87). They are
utilized by the bacterium for infection (88), toxin secretion (89) and virulence (87). Such
uses of phage lysins by A. baumannii have not been reported before. However, A.
baumannii strains are usually poly-lysogenic and some of the prophages are no longer
intact. According to PHAge Search Tool (PHAST) analysis (90), ATCC 17978 possessed
three prophages, two of which are intact and the third questionable. To investigate
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whether the lysins are used to kill DH5α, we are investigating the RNA expression level
of the three lysins in ATCC 17978.

Figure 7.2 Clearing zone around A. baumannii ATCC 17978 colony on E. coli
DH5α agar overlay.
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7.2

PlyF309

7.2.1 BACKGROUND
PlyF309 (GenBank Accession Number KJ740397.1) is the second most active
among the 21 distinct lysins isolated from a genomic library of prophages inside 13 A.
baumannii strains (47). According to a National Center for Biotechnology Information
Basic Local Alignment Search Tool (BLAST) search, it is composed of an N-terminal
catalytic domain (glycosyl hydrolase family 108) and a C-terminal cell-wall binding
domain (peptidoglycan binding 3) (Figure 7.1). The molecular weight of PlyF309 is ~21
kDa and the isoelectric point is 8.40. The lysin was purified and its in vitro bactericidal
activities were analyzed.

Figure 7.3 Domain organization of PlyF309.
7.2.2 MATERIALS AND METHODS
7.2.2.1 Expression and purification
Overnight culture of E. coli DH5α with the pBAD24-PlyF309 construct was
diluted 1:100 in LB containing 100 µg/ml ampicillin and was incubated at 37°C, with
shaking at 200 rpm, until reaching an optical density at 600 nm (OD600) of 0.5. The
expression of PlyF309 was induced by the addition of 0.2% arabinose, and expression
continued overnight at 30°C. The cells were collected, resuspending in 50 mM sodium
phosphate (pH 6.8), and homogenized using an Emulsiflex-C5 homogenizer (Avestin).
The cellular debris was removed by centrifugation (16,000 × g for 45 min at 4°C)
followed by sterile filtration (0.22 µm) to generate a crude lysate. The crude lysate of
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PlyF309 in 50 mM sodium phosphate (pH 6.8) was applied to a HiTrap SP FF column
(GE Healthcare Life Sciences, Uppsala, Sweden) using the Äkta fast protein liquid
chromatography (FPLC) system (GE Healthcare Life Sciences), and fractions were eluted
with a linear gradient of 2 M NaCl. Peaks of interest were pooled and BCA assay was
used to determine the concentration.
7.2.2.2 In vitro bactericidal assays
PlyF309 was biochemically characterized to understand the effects on its in vitro
bactericidal activity by pH, monovalent cation Na+, divalent cations (Ca2+ and Mg2+),
chelating agent EDTA and growth phases (log and stationary). For these assays, A.
baumannii strain #1791 was washed and re-suspended in respective buffer at OD595~1.0
(>108 cfu/mL) and 250 µg/mL of PlyF309 was used. The strain specificity of PlyF309
was investigated with 15 A. baumannii strains #1775-1777 and #1788-#1799 using 250
µg/mL PlyF309, 250 µM EDTA and 37.5 mM Tris buffer (pH 8.0). The experiments
were conducted at least in duplicate.
7.2.3 RESULTS
7.2.3.1 In vitro characterization
PlyF309 was most active in high pH (8.0 and 8.8) and was not tolerant to
monovalent or divalent cations. The higher the EDTA concentrations, the more active
PlyF309. The stationary phase bacteria are the most sensitive among the growth phases
and PlyF309 showed higher activities against strains #1775, #1776, #1777, #1788, #1790,
#1791, #1795, #1798 and #1799 than the rest of the 6 strains (Table 7.1).
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Table 7.1 Summary of PlyF309 activities in different assay conditions
Assay condition

Percent killing

Sodium acetate buffer (pH 5.2)

56.25

Tris-HCl buffer (pH 6.07)

78.57

Tris-HCl buffer (pH 6.8)

60.87

Tris-HCl buffer (pH 8.0)

94.44

Tris-HCl buffer (pH 8.8)

87.50

75 mM NaCl

0

150 mM NaCl

14.29

5 mM CaCl2

0

5 mM MgCl2

0

0.1 mM EDTA

58.33

0.25 mM EDTA

68.18

0.5 mM EDTA

84.25

Early log phase 2 h

15.38

Log phase 4 h

15.38

Late log phase 8 h

35.29

Stationary phase 32 h

50.00

#1775

82.65

#1776

86.80

#1777

66.39

#1788

76.92

#1789

0

#1790

71.43

#1791

75.00

#1792

6.25

#1793

0

#1794

0

#1795

72.73

#1796

0

#1797

16.67

#1798

66

#1799

89.50
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7.2.4 DISCUSSION
The theoretical isoelectric points of PlyF309 catalytic and binding domains are
5.01 and 9.56, respectively, which means that the catalytic domain is negatively charged
and the binding domain is positively charged in the buffers tested. Better killing activities
were achieved with high pH and high EDTA concentrations whereas the cations
diminished the activities, indicating that the outer membrane barrier did impede PlyF309
from getting access to the peptidoglycan. It is also intriguing that PlyF309 showed
growth phase and strain preferences. PlyF309 was also much less active than PlyF307.
However, these results are likely due to the use of higher number of bacteria (108 vs 106
cfu/mL used for PlyF307 assays) while the concentration of the PlyF309 was only 2.5
times higher (250 µg/mL vs 100 µg/mL used for PlyF307 assays).
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